The role of cytokines in disease progression in heart failure

Current Opinion in Cardiology

Volumn 12, Issue 3, 1997, Pages 218-223

  Shan, Kesavan ^a   Kurrelmeyer, Karla ^a   Seta, Yukihiro ^a   Wang, Feng ^a   Dibbs, Ziad ^a   Deswal, Anita ^a   Lee Jackson, Dorellyn ^a   Mann, Douglas L ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTHELIN; INTERLEUKIN 6; NEUROHORMONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

DISEASE COURSE; HEART FAILURE; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030981046     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199705000-00002     Document Type: Review

References (55)

1. Packer M: How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 1993, 71:C3-C11.
2. Packer M: The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992, 20:248-254.
3. Mann DL, Lee-Jackson D, Yokoyama T: Tumor necrosis factor-α and cardiac remodeling. Heart Failure 1995; August/September:166-175.
4. Oral H, Kapadia S, Nakano M, Torre-Amione G, Lee J, Lee-Jackson D, Young JB, Mann DL: Tumor necrosis factor-α and the failing human heart. Clin Cardiol 1995, 18:IV-20-IV-27.
5. Mann DL, Young JB: Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest 1994, 105:897-904.
6. Golfman LS, Hata T, Beamish RE, Dhalla NS: Role of endothelin in heart function in health and disease. Can J Cardiol 1993, 9:635-653.
7. Stewart DJ: Endothelin in cardiopulmonary disease: factor paracrine vs neurohumoral. Eur Heart J 1993, 14:48-54.
8. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL: Basic mechanisms in heart failure: the cytokine hypothesis. J Cardiac Failure 1996, 2:243-249.
9. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M: Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994, 23:1427-1433.
10. Nishida M, Springhorn JP, Kelly RA, Smith TW: Cell-cell signaling between adult rat ventricular myocytes and cardiac microvascular endothelial cells in heterotypic primary culture. J Clin Invest 1993, 91:1934-1941.
11. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Marumo F, Hiroe M: Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin-II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993, 92:398-403.
12. Kelly RA, Eid H, Kramer BK, O'Neill M, Liang BT, Reers M, Smith TW: Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis toxin-sensitive pathway. J Clin Invest 1990, 86:1164-1171.
13. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K, Sugishita Y: Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: marked increase in endothelin-1 production in the failing heart. Circulation 1996, 93:1214-1222. This study provides evidence that the endogenous expression of endothelin-1 in the myocardium may initially by compensatory by providing increased contractile support to the failing myocardium.
14. Jones LG, Rozich JD, Tsutsui H, Cooper G: Endothelin stimulates multiple responses in isolated adult ventricular cardiac myocytes. Am J Physiol 1992, 263:H1447-H1454.
15. Weber KT, Sun Y, Guarda E: Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994, 23:869-877.
16. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996, 384:353-355. This important experimental study in rats shows that blocking the endothelin-A receptor with a specific antagonist prevents myocardial remodeling (dilatation). myocardial fibrosis, and myocardial dysfunction. Thus. this study provides a compelling rationale for the use of endothelin receptor antagonists to prevent disease progression in heart failure.
17. Pacher R, Bergler-Klein J, Globits S, Teufelsbauer H, Schuller M, Krauter A, Ogris E, Rodler S, Wutte M, Hartter E: Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 1993, 71:1293-1299.
18. Loffler BM, Roux S, Kalina B, Clozel M, Clozel J-P: Influence of congestive heart failure on endothelin levels and receptors in rabbits. J Mol Cell Cardiol 1993, 25:407-416.
19. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC: Endothelin in human congestive heart failure. Circulation 1994, 89:1580-1586
20. Teerlink JR, Clozel J-P, Loffler BM, Fischli W, Clozel M: Evolution of plasma endothelin and renin activity levels in a rat model of congestive heart failure. Circulation 1992, 86:1-430.
21. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O: Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995, 346:732-736. This clinical study provides the first evidence that a nonspecific endothelin receptor antagonist (bosentan) is effective is the clinical setting of clinical heart failure in terms of decreasing peripheral vascular resistance and increasing cardiac output.
22. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, Chien KR: Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. J Biol Chem 1990, 265:20555-20562.
23. Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996, 27:633-641. This study shows that elevated levels of endothelin-1 correlate with prognosis for patients with heart failure.
24. Kapadia S, Lee JR, Torre-Amione G, Birdsall HH, Ma TS, Mann DL: Tumor necrosis factor gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995, 96:1042-1052.
25. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL: Tumor necrosis factor-α and tumor necrosis factor receptors in the failing heart. Circulation 1996, 93:704-711. This study was the first to show that both TNF-α mRNA and protein are expressed in the failing hearts of patients with ischemic heart disease and dilated cardiomyopathy, whereas there was no evidence for TNF-α mRNA and protein expression in the nonfailing heart. This study also showed that TNF receptors were downregulated in the failing heart as compared with normal hearts, suggesting that the heart was a target organ for TNF-α in heart failure. Thus, these studies provide an important conceptual understanding of an important source of cytokine production in heart failure.
26. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM: Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996, 347:1151-1155. This study provided important confirmation for the study by Torre-Amione et al. (Circulation 1996, 93:704-711), in that it also demonstrated the presence of TNF-α immunoreactivity in patients with dilated cardiomyopathy. In addition, these authors demonstrated the presence of immunoreactivity for the inducible form of nitric oxide synthase in patients with dilated and ischemic cardiomyopathy.
27. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM: Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996, 347:1151-1155. This study provided important confirmation for the study by Torre-Amione et al. (Circulation 1996, 93:704-711), in that it also demonstrated the presence of TNF-α immunoreactivity in patients with dilated cardiomyopathy. In addition, these authors demonstrated the presence of immunoreactivity for the inducible form of nitric oxide synthase in patients with dilated and ischemic cardiomyopathy.
28. Torre-Amione G, Kapadia S. Lee J, Bies RD, Lebovitz R, Mann DL: Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995, 92:1487-1493.
29. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJE: Tumor necrosis factor-α-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996, 98:2854-2865. This study showed that elevated concentrations of TNF-α were sufficient to produce cell apoptotic (programmed) cell death in culture cardiac myocytes, thus providing a potential link between the elaboration of TNF-α in heart failure and progressive myocyte cell loss.
30. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 223:236-241.
31. Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM: Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996, 77:723-727.
32. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel TH: Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996, 28:964-971. This clinical study shows that elevated levels of TNF-α and TNFR2 are elevated in direct relation to NYHA functional class. In addition, this is the first study to demonstrate the presence of interleukin-1 in patients with heart failure.
33. Milani RV, Mehra MR, Endres S, Eigler A, Cooper S, Lavie Jr, Ventura HO.: The clinical relevance of circulating tumor necrosis factor-α in acute decompensated chronic heart failure without cachexia. Chest 1996, 110:992-997.
34. McMurray J, Abdullah I, Dargie HJ, Shapiro D: Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J 1991, 66:356-358.
35. Wiedermann CJ, Beimpold H, Herold M, Knapp E. Braunsteiner H: Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol 1993, 22:1897-1901.
36. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK: Tumour necrosis factor-alpha in severe congestive cardiac failure. Br Heart J 1993, 70:141-143.
37. Katz SD, Rao R, Berman JW, Schwarz M, Demopoulos L, Bijou R, LeJemtel TH: Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994, 90:12-16.
38. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S: Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994, 72:561-566.
39. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O: Tumor necrosis factor soluble receptors in patients with various degrees of congestive failure. Circulation 1995, 92:1479-1486. This clinical study was the first to document the presence of elevated levels of soluble TNF receptors in patients with heart failure and the first study to show that increased levels of TNF receptors correlated with worse prognosis in patients with heart failure. This study also showed that TNF-α levels were most elevated in the patients with the worst clinical outcomes.
40. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996, 27:1201-1206 This important clinical study was the first to show that both TNF-α and interleukin-6 levels were elevated in direct relation to deteriorating NYHA functional class for patients enrolled in SOLVD. This study also showed that there was no relationship between neurohormonal levels and elevated cytokine levels, suggesting that the elaboration of neurohormones was not the mechanism for cytokine expression in heart failure.
41. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989, 321:280-287.
42. Hegewisch S, Weh HJ, Hossfeld DK: TNF-induced cardiomyopathy. Lancet 1990, ii:294-295.
43. Millar AB, Singer M, Meager A, Foley NM, Johnson NM, Rook GA: Tumor necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome. Lancet 1989, ii:712-713.
44. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992, 327:685-691.
45. The SOLVD Investigators: Effect of enalapril on survival in patents with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
46. Gottleib SS, Hukin ML, Ahern D, Packer M: Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989, 13:1534-1539.
47. Olsson I, Lantz M, Nilsson E, Peetre C, Thysell H, Grubb A, Adolf G: Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989, 42:270-275.
48. Engelmann GL, Novick D, Wallach D: Two tumor necrosis factor-binding proteins purified from human urine. J Biol Chem 1990, 265:1531-1536.
49. Brakebusch C, Nophar Y, Kemper O, Engelmann H, Wallach D: Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. EMBO J 1992, 11:943-950.
50. Kapadia S, Torre-Amione G, Yokoyama T, Mann DL: Soluble tumor necrosis factor binding proteins modulate the negative inotropic effects of TNF-α in vitro. Am J Physiol 1995, 37:H517-H525
51. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992, 175:323-329.
52. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992, 257:387-389.
53. Cannon JG, Meydani SN, Fielding RA, Fiatarone MA, Meydani M, Farhangmehr M, Orencole SF, Blumberg JB, Evans WJ: Acute phase response in exercise. II. Associations between vitamin E, cytokines, and muscle proteolysis. Am J Physiol 1991, 260:1235-1240.
54. Tsutamoto T, Hisanaga T, Wada A, Maeda Y, Fukai D: Plasma concentration of interleukin-6 as a marker of prognosis in patients with chronic congestive heart failure. Circulation 1994, 90:1-381
55. Hirano T: Interleukin-6. In The Cytokine Handbook. Edited by Thompson A. Boston: Academic Press; 1991:169-190.